Denali Therapeutics (DNLI) closed at $20.07 on November 6, 2026, up 1.8% from the previous close, on volume of 1,496,109 shares (30-day average 1,778,759).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
B. Riley Securities Keeps Their Buy Rating on Denali Therapeutics (DNLI)
TipRanks (Thu, 5-Nov 4:16 AM ET)
TipRanks (Wed, 4-Nov 3:40 PM ET)
Cantor Fitzgerald Reaffirms Their Buy Rating on Denali Therapeutics (DNLI)
TipRanks (Wed, 4-Nov 9:05 AM ET)
TipRanks (Wed, 4-Nov 8:38 AM ET)
Denali’s AVLAYAH Momentum and 2027 Clinical Catalysts Support Buy Rating
TipRanks (Wed, 4-Nov 8:27 AM ET)
Denali Therapeutics GAAP EPS of $0.37 beats by $0.72, revenue of $17.77M misses by $5.13M
Seeking Alpha News (Tue, 3-Nov 4:08 PM ET)
Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
Globe Newswire (Tue, 3-Nov 4:01 PM ET)
Here are the major earnings after the close Tuesday
Seeking Alpha News (Tue, 3-Nov 10:00 AM ET)
Globe Newswire (Fri, 30-Oct 9:30 AM ET)
Globe Newswire (Thu, 22-Oct 4:01 PM ET)
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
Denali Therapeutics trades on the NASDAQ stock market under the symbol DNLI.
As of November 6, 2026, DNLI stock price climbed to $20.07 with 1,496,109 million shares trading.
DNLI has a beta of 1.50, meaning it tends to be more sensitive to market movements. DNLI has a correlation of 0.13 to the broad based SPY ETF.
DNLI has a market cap of $3.21 billion. This is considered a Mid Cap stock.
Last quarter Denali Therapeutics reported $18 million in Revenue and -$.64 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$.21.
In the last 3 years, DNLI traded as high as $33.33 and as low as $10.57.
The top ETF exchange traded funds that DNLI belongs to (by Net Assets): VTI, IWM, VB, XBI, VXF.
DNLI has outperformed the market in the last year with a price return of +39.3% while the SPY ETF gained +10.8%. However, in the short term, DNLI had mixed performance relative to the market. It has underperformed in the last 3 months, returning -18.8% vs -4.1% return in SPY. But in the last 2 weeks, DNLI shares have fared better than the market returning +9.0% compared to SPY -3.2%.
DNLI support price is $19.03 and resistance is $20.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DNLI shares will trade within this expected range on the day.
